CA1339925C - Oligosaccharides hepariniques affines pour les facteurs de croissance cellulaires - Google Patents

Oligosaccharides hepariniques affines pour les facteurs de croissance cellulaires

Info

Publication number: CA1339925C
Authority: CA; Canada
Prior art keywords: heparin; oligosaccharides; anionic; sulfate; chains
Prior art date: 1986-04-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA000535040A

Other languages

English (en)

French (fr)

Inventor

Jean-Claude Lormeau

Jean Choay

Maurice Petitou

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi SA

Original Assignee

Sanofi SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-04-17

Filing date

1987-04-16

Publication date

1998-06-23

1987-04-16 Application filed by Sanofi SA filed Critical Sanofi SA

1998-06-23 Application granted granted Critical

1998-06-23 Publication of CA1339925C publication Critical patent/CA1339925C/fr

2015-06-23 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 77
229920001542 oligosaccharide Polymers 0.000 title claims abstract description 71
239000003102 growth factor Substances 0.000 title claims abstract description 39
230000010261 cell growth Effects 0.000 title claims abstract description 29
230000001371 heparinic effect Effects 0.000 title claims description 7
229960002897 heparin Drugs 0.000 claims abstract description 73
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 70
229920000669 heparin Polymers 0.000 claims abstract description 64
125000000129 anionic group Chemical group 0.000 claims abstract description 58
125000002091 cationic group Chemical group 0.000 claims abstract description 22
150000003839 salts Chemical class 0.000 claims abstract description 15
238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims abstract description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 92
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 75
239000000872 buffer Substances 0.000 claims description 60
239000000203 mixture Substances 0.000 claims description 47
239000011780 sodium chloride Substances 0.000 claims description 46
239000000243 solution Substances 0.000 claims description 45
239000000047 product Substances 0.000 claims description 43
229920002683 Glycosaminoglycan Polymers 0.000 claims description 41
238000000034 method Methods 0.000 claims description 33
238000002360 preparation method Methods 0.000 claims description 28
230000000694 effects Effects 0.000 claims description 27
229920002971 Heparan sulfate Polymers 0.000 claims description 23
238000010828 elution Methods 0.000 claims description 20
229920002684 Sepharose Polymers 0.000 claims description 19
238000002523 gelfiltration Methods 0.000 claims description 17
238000001042 affinity chromatography Methods 0.000 claims description 15
239000008194 pharmaceutical composition Substances 0.000 claims description 13
230000008569 process Effects 0.000 claims description 13
150000002016 disaccharides Chemical group 0.000 claims description 12
239000012634 fragment Substances 0.000 claims description 12
GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 11
239000002244 precipitate Substances 0.000 claims description 11
230000001476 alcoholic effect Effects 0.000 claims description 10
238000004587 chromatography analysis Methods 0.000 claims description 10
AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 claims description 9
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 8
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 8
MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 claims description 8
150000001720 carbohydrates Chemical group 0.000 claims description 8
238000005194 fractionation Methods 0.000 claims description 8
230000012010 growth Effects 0.000 claims description 8
-1 modified patterns Chemical class 0.000 claims description 6
239000003826 tablet Substances 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 5
238000001802 infusion Methods 0.000 claims description 5
238000002347 injection Methods 0.000 claims description 5
239000007924 injection Substances 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 5
238000001556 precipitation Methods 0.000 claims description 5
239000002775 capsule Substances 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
239000006187 pill Substances 0.000 claims description 4
230000001376 precipitating effect Effects 0.000 claims description 4
MCHWWJLLPNDHGL-KVTDHHQDSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-3,4-diol Chemical group OC[C@H]1O[C@H](CO)[C@@H](O)[C@@H]1O MCHWWJLLPNDHGL-KVTDHHQDSA-N 0.000 claims description 3
150000001450 anions Chemical class 0.000 claims description 3
239000003153 chemical reaction reagent Substances 0.000 claims description 3
239000012149 elution buffer Substances 0.000 claims description 3
229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
239000011707 mineral Substances 0.000 claims description 3
235000010755 mineral Nutrition 0.000 claims description 3
230000002829 reductive effect Effects 0.000 claims description 3
230000000717 retained effect Effects 0.000 claims description 3
239000002904 solvent Substances 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
239000000443 aerosol Substances 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
239000006071 cream Substances 0.000 claims description 2
238000010253 intravenous injection Methods 0.000 claims description 2
238000004255 ion exchange chromatography Methods 0.000 claims description 2
239000002502 liposome Substances 0.000 claims description 2
239000002674 ointment Substances 0.000 claims description 2
150000002892 organic cations Chemical class 0.000 claims description 2
239000007921 spray Substances 0.000 claims description 2
239000003981 vehicle Substances 0.000 claims description 2
JNYAEWCLZODPBN-KVTDHHQDSA-N (2r,3r,4r)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@@H](O)[C@H]1O JNYAEWCLZODPBN-KVTDHHQDSA-N 0.000 claims 1
230000002785 anti-thrombosis Effects 0.000 claims 1
101150081880 FGF1 gene Proteins 0.000 description 56
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
229960004756 ethanol Drugs 0.000 description 23
235000019441 ethanol Nutrition 0.000 description 23
210000004027 cell Anatomy 0.000 description 22
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
150000002500 ions Chemical class 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 9
239000011159 matrix material Substances 0.000 description 9
239000011734 sodium Substances 0.000 description 9
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
229910052708 sodium Inorganic materials 0.000 description 8
238000012360 testing method Methods 0.000 description 8
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 7
108090000935 Antithrombin III Proteins 0.000 description 7
108010022901 Heparin Lyase Proteins 0.000 description 7
239000000499 gel Substances 0.000 description 7
108010083213 heparitinsulfate lyase Proteins 0.000 description 7
239000002609 medium Substances 0.000 description 7
238000000926 separation method Methods 0.000 description 7
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
229930195725 Mannitol Natural products 0.000 description 6
230000024245 cell differentiation Effects 0.000 description 6
239000000594 mannitol Substances 0.000 description 6
235000010355 mannitol Nutrition 0.000 description 6
230000035755 proliferation Effects 0.000 description 6
150000003431 steroids Chemical class 0.000 description 6
239000000126 substance Substances 0.000 description 6
102100022977 Antithrombin-III Human genes 0.000 description 5
235000015278 beef Nutrition 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
239000003814 drug Substances 0.000 description 5
210000002889 endothelial cell Anatomy 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
238000005342 ion exchange Methods 0.000 description 5
238000003756 stirring Methods 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
230000032823 cell division Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
230000000472 traumatic effect Effects 0.000 description 4
PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
208000014674 injury Diseases 0.000 description 3
230000014508 negative regulation of coagulation Effects 0.000 description 3
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
230000009467 reduction Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000037303 wrinkles Effects 0.000 description 3
102000004411 Antithrombin III Human genes 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
206010010356 Congenital anomaly Diseases 0.000 description 2
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010029113 Neovascularisation Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000008351 acetate buffer Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
238000013019 agitation Methods 0.000 description 2
AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
229960005348 antithrombin iii Drugs 0.000 description 2
210000002403 aortic endothelial cell Anatomy 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
210000001043 capillary endothelial cell Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000000470 constituent Substances 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000003328 fibroblastic effect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
150000002337 glycosamines Chemical class 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003902 lesion Effects 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000005022 packaging material Substances 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000017423 tissue regeneration Effects 0.000 description 2
230000002792 vascular Effects 0.000 description 2
PURMPUDWXOWORS-SKNVOMKLSA-N (2r,3s,4s,5r)-2,3,4-trihydroxy-6-oxo-5-sulfooxyhexanoic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](OS(O)(=O)=O)C=O PURMPUDWXOWORS-SKNVOMKLSA-N 0.000 description 1
LKAPTZKZHMOIRE-KVTDHHQDSA-N (2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbaldehyde Chemical group OC[C@H]1O[C@H](C=O)[C@@H](O)[C@@H]1O LKAPTZKZHMOIRE-KVTDHHQDSA-N 0.000 description 1
UDQPBAKZZSWNSE-MBMOQRBOSA-N (2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carboxylic acid Chemical group OC[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@@H]1O UDQPBAKZZSWNSE-MBMOQRBOSA-N 0.000 description 1
HMUBCRODSGHUNN-SQSKTBJTSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol (2R,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.O=C[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O HMUBCRODSGHUNN-SQSKTBJTSA-N 0.000 description 1
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
QCWQUWUCARNNRI-UHFFFAOYSA-N 3-ethyl-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbaldehyde Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C=O)C(CC)=C2 QCWQUWUCARNNRI-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
KLYCPFXDDDMZNQ-UHFFFAOYSA-N Benzyne Chemical compound C1=CC#CC=C1 KLYCPFXDDDMZNQ-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
102100037362 Fibronectin Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
229940121797 Glycosaminoglycan inhibitor Drugs 0.000 description 1
235000005612 Grewia tenax Nutrition 0.000 description 1
244000041633 Grewia tenax Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
241000605114 Pedobacter heparinus Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000000558 Varicose Ulcer Diseases 0.000 description 1
YQKFJYBRZVNXKQ-UHFFFAOYSA-N [Na].BC#N Chemical compound [Na].BC#N YQKFJYBRZVNXKQ-UHFFFAOYSA-N 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000009674 basal proliferation Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
150000001767 cationic compounds Chemical class 0.000 description 1
230000036978 cell physiology Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
210000003711 chorioallantoic membrane Anatomy 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
230000000459 effect on growth Effects 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000009843 endothelial lesion Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
239000002634 heparin fragment Substances 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
235000021178 picnic Nutrition 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000012286 potassium permanganate Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000011403 purification operation Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
150000004044 tetrasaccharides Chemical class 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Materials Engineering (AREA)
Polymers & Plastics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA000535040A 1986-04-17 1987-04-16 Oligosaccharides hepariniques affines pour les facteurs de croissance cellulaires Expired - Fee Related CA1339925C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR86-05546		1986-04-17
FR8605546A FR2597484B1 (fr)	1986-04-17	1986-04-17	Glycosaminoglycanes de type heparine ou heparane-sulfate dotes d'une activite sur la division et la differentiation cellulaires, leur preparation et leurs applications therapeutiques.

Publications (1)

Publication Number	Publication Date
CA1339925C true CA1339925C (fr)	1998-06-23

Family

ID=9334346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000535040A Expired - Fee Related CA1339925C (fr)	1986-04-17	1987-04-16	Oligosaccharides hepariniques affines pour les facteurs de croissance cellulaires

Country Status (8)

Country	Link
US (1)	US5034520A (de)
EP (1)	EP0244298B1 (de)
JP (1)	JPS6366192A (de)
AT (1)	ATE114674T1 (de)
CA (1)	CA1339925C (de)
DE (1)	DE3750785T2 (de)
FR (1)	FR2597484B1 (de)
PT (1)	PT84719B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5273900A (en) *	1987-04-28	1993-12-28	The Regents Of The University Of California	Method and apparatus for preparing composite skin replacement
PT93847A (pt) *	1989-04-24	1990-11-20	Harvard College	Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
NO921495L (no) *	1991-04-16	1992-10-19	Seikagaku Kogyo Co Ltd	Oligosakkarid og fremgangsmaate for dets fremstilling
US5145956A (en) *	1991-12-11	1992-09-08	Glycomed Incorporated	Method for separation of anionic oligosaccharides
GB9206291D0 (en) *	1992-03-23	1992-05-06	Cancer Res Campaign Tech	Oligosaccharides having growth factor binding affinity
GB2266239B (en) *	1992-03-25	1996-03-06	Jevco Ltd	Wound healing compositions containing chondroitin sulphate oligosaccharides
US5861382A (en) *	1992-05-01	1999-01-19	Yeda Research And Development Co. Ltd.	Methods for regulation of active TNF-α
US6750207B1 (en) *	1992-05-01	2004-06-15	Yeda Research And Development Co. Ltd.	Compositions for the regulation of cytokine activity
FR2691066B1 (fr) *	1992-05-15	1995-06-09	Sanofi Elf	Utilisation de glycosaminoglycanes exogenes, de leurs analogues ainsi que de leurs fragments, fractions et derives, pour la preparation de medicaments destines au traitement de thrombopenies.
EP1095657B1 (de) *	1992-11-10	2007-01-10	Yeda Research And Development Co. Ltd.	Zusammenstellung zur Regulierung der Zytokinaktivität
GB9306255D0 (en) *	1993-03-25	1993-05-19	Cancer Res Campaign Tech	Heparan sulphate oligosaccharides having hepatocyte growth factor binding affinity
US5583121A (en) *	1994-01-12	1996-12-10	Michigan State University	Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US6127347A (en) *	1994-01-12	2000-10-03	Univ Michigan	Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
WO1996023003A1 (en) *	1995-01-27	1996-08-01	Amrad Operations Pty. Ltd.	A therapeutic molecule
AU702500B2 (en) *	1995-04-28	1999-02-25	Australian National University, The	Preparation and use of sulfated oligosaccharides
AUPN261895A0 (en) *	1995-04-28	1995-05-18	Australian National University, The	Preparation and use of sulfated oligosaccharides
US5646130A (en) *	1995-06-30	1997-07-08	Ocean University Of Oingdao	Low molecular weight sulfated polysaccharides and uses thereof
WO1999004801A1 (en) *	1997-07-28	1999-02-04	Rijks Universiteit Leiden	Use of sulfated glycosaminoglycans for treating of retinopathy
DE19747195A1 (de) *	1997-10-24	1999-04-29	Knoll Ag	Verwendung von Glykosaminoglykanen zur Herstellung von pharmazeutischen Zubereitungen zur Behandlung von mit Diabetes assoziierten Augenkrankheiten
JP4633232B2 (ja) *	2000-06-22	2011-02-16	生化学工業株式会社	成長因子誘導剤
AU2002236477A1 (en) *	2000-11-21	2002-06-03	The Texas A & M University System	Fgf-affinity chromatography
US7285536B2 (en) *	2001-12-05	2007-10-23	Yeda Research And Development Co., Ltd.	Anti-cancer therapeutic compounds
US20040171819A1 (en)	2002-10-10	2004-09-02	Aventis Pharma S.A.	Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
WO2005079817A1 (en) *	2004-02-18	2005-09-01	The Texas A & M University System	Affinity purified heparin/heparan sulfate for controlling the biological activity of the fgf receptor
JPWO2005092348A1 (ja) *	2004-03-29	2008-02-07	敏一中村	ヘパリン様オリゴ糖含有ｈｇｆ産生促進薬剤
US20060183712A1 (en) *	2005-02-17	2006-08-17	The Texas A&M University System	Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
JP2006291028A (ja) *	2005-04-11	2006-10-26	Q P Corp	低分子ヘパリンまたはその塩、ならびにその製造方法
US20110166078A1 (en) *	2008-09-15	2011-07-07	Endotis Pharma	Oligosaccharide compounds for use in mobilising stem cells
FR2949115B1 (fr) *	2009-08-14	2012-11-02	Sanofi Aventis	OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL61201A (en) *	1979-10-05	1984-09-30	Choay Sa	Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
DE3373782D1 (en) *	1982-12-20	1987-10-29	Harvard College	Inhibition of angiogenesis
FR2553287B1 (fr) *	1983-10-18	1986-09-12	Choay Sa	Compositions a base de mucopolysaccharides ou d'oligosaccharides, notamment a base de fractions ou fragments d'heparine, appropriees au traitement de desordres de la proliferation cellulaire
US4847338A (en) *	1985-03-28	1989-07-11	University Of Iowa Research Foundation	Low molecular weight heparin fragments as inhibitors of complement activation

1986
- 1986-04-17 FR FR8605546A patent/FR2597484B1/fr not_active Expired
1987
- 1987-04-16 US US07/039,471 patent/US5034520A/en not_active Expired - Fee Related
- 1987-04-16 DE DE3750785T patent/DE3750785T2/de not_active Expired - Fee Related
- 1987-04-16 PT PT84719A patent/PT84719B/pt not_active IP Right Cessation
- 1987-04-16 AT AT87400884T patent/ATE114674T1/de active
- 1987-04-16 JP JP62092122A patent/JPS6366192A/ja active Pending
- 1987-04-16 EP EP87400884A patent/EP0244298B1/de not_active Expired - Lifetime
- 1987-04-16 CA CA000535040A patent/CA1339925C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PT84719B (pt)	1989-12-29
FR2597484A1 (fr)	1987-10-23
DE3750785D1 (de)	1995-01-12
FR2597484B1 (fr)	1988-12-23
US5034520A (en)	1991-07-23
JPS6366192A (ja)	1988-03-24
DE3750785T2 (de)	1995-06-22
EP0244298A2 (de)	1987-11-04
ATE114674T1 (de)	1994-12-15
EP0244298A3 (en)	1988-09-21
EP0244298B1 (de)	1994-11-30
PT84719A (fr)	1987-05-01

Legal Events

Date	Code	Title	Description
2001-06-26	MKLA	Lapsed

Publication	Publication Date	Title
EP0244298B1 (de)	1994-11-30	Oligosaccharide von Heparin mit einer Affinität für Faktoren von Zellwachstum
CA1327968C (fr)	1994-03-22	Heparines de bas poids moleculaire, a structure reguliere leur preparation et leurs applications biologiques
EP0214879B1 (de)	1990-11-22	Verfahren zur Sulphatierung von Glykosaminoglykanen, daraus hergestellte Glykosaminoglykane und ihre biologischen Verwendungen
EP0027089B1 (de)	1986-01-22	Oligosaccharidfraktionen und Oligosaccharide mit biologischen Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendungen als Arzneimittel
EP0302034B1 (de)	1993-04-28	Heparinderivate, Verfahren zu deren Herstellung und Verwendung für pharmazeutische Zwecke
US5008253A (en)	1991-04-16	Sulfoamino derivatives of chondroitin sulfates of dermatan sulfate and of hyaluronic acid and their pharmacological properties
JPH02206601A (ja)	1990-08-16	抗トロンビン作用を有するオリゴサッカライドフラクションの製法
CN1379781A (zh)	2002-11-13	新的低聚糖、其制备方法及其药物组合物
EP0140781A2 (de)	1985-05-08	Heparinderivathaltige Zusammensetzungen, die besonders zur Behandlung von Störungen durch Zellwucherung geeignet sind
EP0165134B1 (de)	1993-02-03	Oligosaccharide, ihre Herstellung durch Synthese und ihre biologische Verwendung
EP0064452B1 (de)	1985-04-17	Kurzkettige Oligosaccharide mit biologischen Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendungen als Arzneimittel
EP0163582B1 (de)	1990-09-26	Medikamente welche die freifliessenden Eigenschaften von Blut verbessern und die Verwendung in Therapeutika
CN1529715A (zh)	2004-09-15	K5多糖高硫酸化衍生物及其制备方法
EP0582665A1 (de)	1994-02-16	Sulfatierte polysaccharide als hemmungsmittel zur glatten-muskelzellen-wucherung
JP5053512B2 (ja)	2012-10-17	非常に大きい硫酸化度を持つｋ５多糖体のエピマー化誘導体
FR2857971A1 (fr)	2005-01-28	Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
CN115124629B (zh)	2023-06-30	一种海藻多糖钙的制备及其应用
FR2495935A1 (fr)	1982-06-18	Fractions mucopolysaccharidiques possedant des proprietes biologiques, leur procede de preparation et leur application en tant que medicaments
RU2333222C2 (ru)	2008-09-10	Эпимеризованные производные полисахарида к5 с высокой степенью сульфатирования
FR2572080A1 (fr)	1986-04-25	Procede de preparation de compositions de mucopolysaccharides dotees d'une activite antithrombotique elevee, les compositions obtenues et leur application en tant que medicaments